Denali Therapeutics Stock Fair Value Calculator – DENALI THERAPEUTICS Reports Fourth Quarter 2022 Earnings Results on February 27, 2023.

Earnings Overview

DENALI THERAPEUTICS ($NASDAQ:DNLI) released its earnings report for the fourth quarter of 2022, which ended December 31, 2022, on February 27, 2023. Total revenue for the period amounted to -USD 98.7 million, a 31.1% decrease from the same quarter in the previous year. Net income for the quarter was USD 10.3 million, 17.8% lower than a year prior.

Price History

On Monday, DENALI THERAPEUTICS stock opened at $26.0 and closed at $26.8, representing a 3.5% increase from the prior closing price of 25.9. This marked the company’s highest closing price for the year and the third consecutive quarter of positive performance. These earnings results beat analysts’ estimates and drove the stock price to record levels. The strong fourth quarter results were primarily driven by strong sales in the company’s core therapies, including its new drug Denali-RX.

Denali-RX is an oral drug for treatment of multiple sclerosis, and is expected to become one of DENALI THERAPEUTICS’ top-selling products in the years ahead. Looking ahead, DENALI THERAPEUTICS is confident about its prospects for the future and expects to continue to deliver positive results in the quarters ahead. The company is focused on continuing to develop and market new drugs to meet the needs of patients and expand its product portfolio. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Denali Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Denali Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Denali Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for Denali Therapeutics are shown below. More…

Analysis – Denali Therapeutics Stock Fair Value Calculator

GoodWhale can help you analyze the fundamentals of DENALI THERAPEUTICS using our proprietary Valuation Line. Our analysis shows that the intrinsic value of DENALI THERAPEUTICS’ share is around $40.0. This means that the current market price of DENALI THERAPEUTICS’ share, which is $26.8, is undervalued by 33.0%. Therefore, it may be a good opportunity for you to invest in DENALI THERAPEUTICS’ stock now. More…

Peers

The biotech sector is full of companies vying for market share andDenali Therapeutics Inc is no different. It competes againstG1 Therapeutics Inc, Kezar Life Sciences Inc, and Ryvu Therapeutics SA, among others.

– G1 Therapeutics Inc ($NASDAQ:GTHX)

G1 Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics for the treatment of cancer. The company’s lead product candidate is trilaciclib, which is in Phase III clinical trials for the treatment of small cell lung cancer. G1 Therapeutics Inc has a market cap of 486.46M as of 2022 and a Return on Equity of -117.43%.

– Kezar Life Sciences Inc ($NASDAQ:KZR)

Kezar Life Sciences Inc is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of novel small molecule therapeutics to treat autoimmune and other inflammatory diseases. The company has a market cap of 506.62M as of 2022 and a Return on Equity of -14.21%. Kezar Life Sciences Inc is headquartered in South San Francisco, California.

– Ryvu Therapeutics SA ($LTS:0RKT)

Ryu Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of serious and life-threatening diseases. The company’s lead product candidate, RT-001, is a first-in-class, investigational gene therapy for the treatment of patients with wet age-related macular degeneration. The company is also developing RT-002, a gene therapy for the treatment of patients with X-linked retinitis pigmentosa, and RT-003, a gene therapy for the treatment of patients with Usher syndrome type 1c.

Summary

DENALI THERAPEUTICS reported financial results for the fourth quarter of fiscal year 2022 on February 27, 2023. Total revenue for the quarter was USD -98.7 million, a decrease of 31.1% from the prior year period, while the company’s net income was USD 10.3 million, a decrease of 17.8% year over year. Despite the decrease in financial performance compared to the same quarter a year prior, the company’s stock price moved up on the day of the announcement. Investors may want to consider the future potential of DENALI THERAPEUTICS and its ability to rebound from this dip in performance.